Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial

Abstract

The continuous emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants led to a rapid decline in protection efficacy and neutralizing titers even after three doses of COVID-19 vaccines. Here, we report an open-labeled Phase I clinical trial of a modified mRNA vaccine (SYS6006) as a fourth-dose booster in healthy adults. Eighteen eligible participants, who had completed three doses of inactivated COVID-19 vaccines, received a fourth boosting dose of SYS6006-20 μg. Eighteen convalescent COVID-19 patients were enrolled for the collection of serum samples as a comparator of immunogenicity. The primary endpoint of this trial was titers of anti-receptor binding domain of spike glycoprotein (RBD) antibodies of the Omicron strain (BA.2 and BA.4/5) in serum; titers of neutralizing antibodies against pseudovirus of the Omicron strain (BA.2 and BA.4/5). The secondary endpoint was the incidence of adverse events within 30 days after the boosting. The exploratory endpoint was the cellular immune responses (interferon gamma, IFN-γ). This trial was registered with the Chinese Clinical Trial Registry website. No serious adverse events were reported within 30 days after vaccination. No Grade 3 fever or serious adverse event was reported in the SYS6006 group. Notably, SYS6006 elicited higher titers and longer increases in anti-RBD antibodies and neutralizing antibodies (>90 days) compared with the convalescent group (P < 0.0001) against Omicron strain (BA.2 and BA.4/5). Besides, higher positive spots of T-cell-secreting IFN-γ were observed in the SYS6006 group than those in the convalescent group (P < 0.05). These data demonstrated that SYS6006 was well tolerated and highly immunogenic, generating a stronger and more durable immune response against different variants of SARS-CoV-2.

Keywords

SARS-CoV-2 / mRNA vaccine / SYS6006 / heterologous boosting / clinical trial

References

[1] World Health Organization [WHO]. WHO Coronavirus (COVID-19) Dashboard. 2022.

[2] Eroglu B , Nuwarda RF , Ramzan I et al. A narrative review of COVID-19 vaccines. Vaccines (Basel) 2022; 10: 62.

[3] Basta NE , Moodie EEM . COVID-19 Vaccine Tracker. 2022. Available at the website of COVID19 Vaccine Tracker.

[4] Goldberg Y , Mandel M , Bar-On YM et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med 2021; 385: e85.

[5] DeGrace MM , Ghedin E , Frieman MB et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature 2022; 605: 640- 52.

[6] Cheng SMS , Mok CKP , Leung YWY et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med 2022; 28: 486- 9.

[7] Klemis V , Schmidt T , Schub D et al. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat Commun 2022; 13: 4710.

[8] Harari S , Tahor M , Rutsinsky N , et al . Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nat Med 2022; 28: 1501- 8.

[9] Zuo F , Abolhassani H , Du L et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun 2022; 13: 2670.

[10] Costa Clemens SA , Weckx L , Clemens R et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 2022; 399: 521- 9.

[11] Jin P , Guo X , Chen W et al. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ ZF2001): a randomized, observer-blinded, placebo-controlled trial. PLoS Med 2022; 19: e1003953.

[12] Behrens GMN , Barros-Martins J , Cossmann A et al. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Commun 2022; 13: 4872.

[13] Liu X , Shaw RH , Stuart ASV et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (ComCOV): a single-blind, randomised, non-inferiority trial. Lancet 2021; 398: 856- 69.

[14] World Health Organization.Interim Recommendations for Heterologous COVID-19 Vaccine Schedules: Interim Guidance. World Heal. Organ. 2021. Available at the website of World Health Organization.

[15] Au WY , Cheung PPH . Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022; 377: e069989.

[16] Canetti M , Barda N , Gilboa M et al. Six-month follow-up after a fourth BNT162b2 vaccine dose. N Engl J Med 2022; 387: 2092- 4.

[17] Magen O , Waxman JG , Makov-Assif M et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2022; 386: 1603- 14.

[18] Charland N , Gobeil P , Pillet S et al. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. NPJ Vaccines 2022; 7: 142.

[19] Ai J , Zhang H , Zhang Q et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern. Cell Res 2022; 32: 103- 6.

[20] Tabarsi P , Anjidani N , Shahpari R et al. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clin Microbiol Infect 2022; 28: 1263- 71.

[21] Boulton S , Poutou J , Martin NT et al. Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. Mol Ther 2022; 30: 1885- 96.

[22] Tan AT , Linster M , Tan CW et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep 2021; 34: 108728.

[23] Zuo J , Dowell AC , Pearce H et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol 2021; 22: 620- 6.

[24] Keech C , Albert G , Cho I et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; 383: 2320- 32.

[25] Richmond P , Hatchuel L , Dong M et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397: 682- 94.

[26] Polack FP , Thomas SJ , Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603- 15.

[27] Baden LR , El Sahly HM , Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 16.

[28] Kremsner PG , Ahuad Guerrero RA , Arana-Arri E et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2022; 22: 329- 40.

[29] Cao Y , Hao X , Wang X et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res 2022; 32: 107- 9.

[30] Tanriover MD , Doğanay HL , Akova M et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398: 213- 22.

[31] Ramanathan K , Antognini D , Combes A et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2020; 21: 39- 51.

[32] Xu K , Lei W , Kang B et al. A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Front Immunol 2023; 13: 1051576.

[33] Chen X , Yan X , Sun K et al. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022. Emerg Microbes Infect 2022; 11: 2800- 7.

[34] Mulligan MJ , Lyke KE , Kitchin N et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586: 589- 93.

[35] Jackson LA , Anderson EJ , Rouphael NG et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920- 31.

[36] Li J , Hui A , Zhang X et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med 2021; 27: 1062- 70.

[37] Anderson EJ , Rouphael NG , Widge AT et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427- 38.

[38] Ferdinands JM , Rao S , Dixon BE et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ 2022; 379: e072141.

[39] Gram MA , Emborg HD , Schelde AB et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: a nationwide Danish cohort study. PLoS Med 2022; 19: e1003992.

[40] Choudhary MC , Chew KW , Deo R et al. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol 2022; 7: 1906- 17.

[41] Woodbridge Y , Amit S , Huppert A et al. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection. Nat Commun 2022; 13: 6706.

[42] Wang J , Deng C , Liu M et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat Commun 2022; 13: 6866.

[43] Lin DY , Gu Y , Xu Y et al. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 2022; 328: 1415- 26.

[44] Sobieszczyk ME , Maaske J , Falsey AR et al. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest 2022; 132: e160565.

[45] Human N , Duke BD . China’s COVID vaccines have been crucial: now immunity is wanning. Nature 2021; 598: 398- 9.

[46] Chalkias S , Eder F , Essink B et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med 2022; 28: 2388- 97.

[47] Feng S , Phillips DJ , White T et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 2032- 40.

[48] Goldblatt D , Alter G , Crotty S et al. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev 2022; 310: 6- 26.

[49] Chen GL , Li XF , Dai XH et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 2022; 3: e193- 202.

[50] Hillus D , Schwarz T , Tober-Lau P et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med 2021; 9: 1255- 65.

[51] Kaabi NA , Yang YK , Du LF et al. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun 2022; 13: 3654.

[52] Folegatti PM , Ewer KJ , Aley PK et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467- 78.

RIGHTS & PERMISSIONS

The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.